HRP20231175T1 - Postupci kultiviranja stanica - Google Patents
Postupci kultiviranja stanica Download PDFInfo
- Publication number
- HRP20231175T1 HRP20231175T1 HRP20231175TT HRP20231175T HRP20231175T1 HR P20231175 T1 HRP20231175 T1 HR P20231175T1 HR P20231175T T HRP20231175T T HR P20231175TT HR P20231175 T HRP20231175 T HR P20231175T HR P20231175 T1 HRP20231175 T1 HR P20231175T1
- Authority
- HR
- Croatia
- Prior art keywords
- cysteine
- seq
- cystine
- sequence
- similarity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17204978.5A EP3492582A1 (en) | 2017-12-01 | 2017-12-01 | Cell culture methods |
| PCT/EP2018/083010 WO2019106091A1 (en) | 2017-12-01 | 2018-11-29 | Cell culture methods |
| EP18811257.7A EP3717631B1 (en) | 2017-12-01 | 2018-11-29 | Cell culture methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231175T1 true HRP20231175T1 (hr) | 2024-01-19 |
Family
ID=60629439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231175TT HRP20231175T1 (hr) | 2017-12-01 | 2018-11-29 | Postupci kultiviranja stanica |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11859203B2 (https=) |
| EP (2) | EP3492582A1 (https=) |
| JP (1) | JP7422072B2 (https=) |
| KR (1) | KR20200092348A (https=) |
| CN (1) | CN111417715B (https=) |
| BR (1) | BR112020010473A2 (https=) |
| CA (1) | CA3083680A1 (https=) |
| EA (1) | EA202091349A1 (https=) |
| ES (1) | ES2963653T3 (https=) |
| HR (1) | HRP20231175T1 (https=) |
| HU (1) | HUE063812T2 (https=) |
| PL (1) | PL3717631T3 (https=) |
| SG (1) | SG11202004935UA (https=) |
| WO (1) | WO2019106091A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3492582A1 (en) | 2017-12-01 | 2019-06-05 | UCB Biopharma SPRL | Cell culture methods |
| CN112391350A (zh) * | 2020-10-30 | 2021-02-23 | 北京双鹭药业股份有限公司 | 高效表达抗egfr单克隆抗体细胞的筛选培养方法 |
| GB202105424D0 (en) | 2021-04-16 | 2021-06-02 | UCB Biopharma SRL | Cell culture processes |
| EP4166651A1 (en) | 2021-10-18 | 2023-04-19 | Evonik Operations GmbH | Methods and composition to increase cellular glutathione level |
| WO2023067626A1 (en) * | 2021-10-20 | 2023-04-27 | Dr. Reddy's Laboratories Limited | A cell culture process to produce an antibody composition |
| EP4484567A4 (en) * | 2022-02-21 | 2026-04-01 | Chugai Pharmaceutical Co Ltd | PERFUSION CULTURE METHOD |
| WO2024024720A1 (ja) * | 2022-07-25 | 2024-02-01 | 味の素株式会社 | 細胞培養用の培地 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| EP1482031B1 (en) | 1996-08-30 | 2015-10-28 | Life Technologies Corporation | Serum-free mammalian cell culture medium, and uses thereof |
| CN101332157B (zh) * | 1998-10-09 | 2012-01-11 | 味之素株式会社 | 半胱氨酸衍生物 |
| KR20050070512A (ko) | 2003-12-30 | 2005-07-07 | 삼성정밀화학 주식회사 | 재조합 단백질의 생산성을 증가시키는 무혈청 배지 및동물세포 배양방법 |
| TWI456062B (zh) * | 2006-09-13 | 2014-10-11 | Abbvie Inc | 細胞培養改良 |
| EP2500415A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| AU2011246502B2 (en) | 2010-04-26 | 2014-08-28 | Novartis Ag | Improved cell cultivation process |
| WO2013158275A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Cell culture methods to reduce acidic species |
| US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
| BR112016027797A2 (pt) | 2014-06-18 | 2017-10-31 | Medimmune Llc | métodos e meios de cultura de células compreendendo n-acetilcisteína |
| US11220668B2 (en) * | 2016-04-28 | 2022-01-11 | Merck Patent Gmbh | Method for reducing the trisulfide level in proteins |
| EP3492582A1 (en) | 2017-12-01 | 2019-06-05 | UCB Biopharma SPRL | Cell culture methods |
-
2017
- 2017-12-01 EP EP17204978.5A patent/EP3492582A1/en not_active Ceased
-
2018
- 2018-11-29 KR KR1020207018104A patent/KR20200092348A/ko not_active Abandoned
- 2018-11-29 US US16/768,091 patent/US11859203B2/en active Active
- 2018-11-29 SG SG11202004935UA patent/SG11202004935UA/en unknown
- 2018-11-29 JP JP2020529609A patent/JP7422072B2/ja active Active
- 2018-11-29 CA CA3083680A patent/CA3083680A1/en active Pending
- 2018-11-29 HR HRP20231175TT patent/HRP20231175T1/hr unknown
- 2018-11-29 PL PL18811257.7T patent/PL3717631T3/pl unknown
- 2018-11-29 BR BR112020010473-6A patent/BR112020010473A2/pt not_active IP Right Cessation
- 2018-11-29 ES ES18811257T patent/ES2963653T3/es active Active
- 2018-11-29 HU HUE18811257A patent/HUE063812T2/hu unknown
- 2018-11-29 WO PCT/EP2018/083010 patent/WO2019106091A1/en not_active Ceased
- 2018-11-29 EA EA202091349A patent/EA202091349A1/ru unknown
- 2018-11-29 CN CN201880076960.2A patent/CN111417715B/zh active Active
- 2018-11-29 EP EP18811257.7A patent/EP3717631B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3717631T3 (pl) | 2024-03-04 |
| JP7422072B2 (ja) | 2024-01-25 |
| EA202091349A1 (ru) | 2020-08-20 |
| US20200308536A1 (en) | 2020-10-01 |
| SG11202004935UA (en) | 2020-06-29 |
| EP3717631A1 (en) | 2020-10-07 |
| US11859203B2 (en) | 2024-01-02 |
| CA3083680A1 (en) | 2019-06-06 |
| JP2021503938A (ja) | 2021-02-15 |
| BR112020010473A2 (pt) | 2020-11-24 |
| KR20200092348A (ko) | 2020-08-03 |
| WO2019106091A1 (en) | 2019-06-06 |
| EP3717631B1 (en) | 2023-08-30 |
| CN111417715B (zh) | 2024-08-27 |
| CN111417715A (zh) | 2020-07-14 |
| HUE063812T2 (hu) | 2024-02-28 |
| EP3717631C0 (en) | 2023-08-30 |
| ES2963653T3 (es) | 2024-04-01 |
| EP3492582A1 (en) | 2019-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231175T1 (hr) | Postupci kultiviranja stanica | |
| RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
| AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| RU2010105233A (ru) | Гуманизированные антитела против cd79b и иммуноконъюгаты и способы применения | |
| NZ581418A (en) | Novel rabbit antibody humanization methods and humanized rabbit antibodies | |
| AR097651A1 (es) | Métodos y composiciones que comprenden polipéptidos recombinantes purificados | |
| HRP20190932T1 (hr) | Molekule protutijela koje se vežu na il-17a i il-17f | |
| PE20121646A1 (es) | Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica | |
| PE20181089A1 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| PE20211605A1 (es) | ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS | |
| AR110659A1 (es) | Proteínas de unión a antígenos anti-neuropilin y método para su uso | |
| HRP20211794T1 (hr) | Humana antitijela za pd-1 | |
| RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
| MX363226B (es) | Formulaciones de anticuerpos. | |
| RU2016151235A (ru) | Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус | |
| RU2012131671A (ru) | Способ полипептидной модификации для очистки полипептидных мультимеров | |
| JP2013056885A5 (https=) | ||
| HRP20191983T1 (hr) | Konstrukti protutijela za cdh19 i cd3 | |
| RU2010119450A (ru) | Антитело против bst2 | |
| HRP20150639T1 (hr) | Postupak za proäśišä†avanje proteina | |
| RU2014127287A (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
| CR20240482A (es) | Anticuerpos anti-tl1a y métodos de uso de los mismos | |
| AR105938A1 (es) | Anticuerpo anti-epha4 | |
| RU2014145536A (ru) | Антитело против adamts-5, его производные и их применение | |
| RU2013105487A (ru) | Антитела против нейропилина и способы их применения |